Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
150 participants
OBSERVATIONAL
2020-02-20
2020-04-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigation the Effect of Montelukast in COVID-19
NCT04718285
An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)
NCT00092885
A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)
NCT00960141
A Study to Evaluate the Safety of Combination Montelukast/Loratadine in Mexican Participants With Allergic Rhinitis (MK-0476A-484)
NCT01673620
Montelukast as a Controller of Atopic Syndrome
NCT00559546
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Investigators have performed an observational study of 100 hospitalized COVID-19 patients while assessing the safety and efficacy of HCQ, ML, and IV as individual therapy and in combination with each other. ECG, interleukin levels, LFTs, blood profiles were continuously monitored throughout the study.
The aim was to observe participants treated with ML and monitor the inflammatory markers to see whether they increase or decrease and whether an increase in survival rate is observed. The findings have shown that combinational therapy of ML with continuous observation of liver/kidney profiles and QTc prolongation can provide robust recovery with suppression of cytokines.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hydroxychloroquine and Montelukast
Group 1 was given Standard of care (SOC) + HCQ + Montelukast
Montelukast
An FDA approved medicine to treat asthmatic patients
Hydroxychloroquine
An FDA approved antiarthritis drug
Montelukast
Group 2 was given Standard of care (SOC) + Montelukast
Montelukast
An FDA approved medicine to treat asthmatic patients
Hydroxychloroquine
Group 3 was given Standard of care (SOC) + HCQ
Hydroxychloroquine
An FDA approved antiarthritis drug
Hydroxychloroquine, Montelukast and Invermectin
Group 4 was given Standard of care (SOC) + Montelukast + HCQ and Ivermectin
Montelukast
An FDA approved medicine to treat asthmatic patients
Hydroxychloroquine
An FDA approved antiarthritis drug
Ivermectin
An FDA approved anti-parasitic medicine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Montelukast
An FDA approved medicine to treat asthmatic patients
Hydroxychloroquine
An FDA approved antiarthritis drug
Ivermectin
An FDA approved anti-parasitic medicine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who are not directly admitted to ICU
Exclusion Criteria
* Patients with age \> 80
* Patient with any known allergies to montelukast
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Shaukat Khanum Memorial Cancer Hospital & Research Centre
OTHER
Shanghai Jiao Tong University School of Medicine
OTHER
Teesside University
OTHER
University of Sargodha
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Muhammad Fayyaz ur Rehman
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wei Zhang, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China
Muhammad Rehman Akram, MBBS
Role: PRINCIPAL_INVESTIGATOR
Shaukat Khanum Memorial Cancer Hospital & Research Centre, Johar Town, Lahore, Pakistan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China
Shanghai, , China
Shaukat Khanum Memorial Cancer Hospital & Research Centre, Johar Town, Lahore, Pakistan
Lahore, Punjab Province, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01032020-7
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.